Character Biosciences, Bausch + Lomb to collaborate on development of AMD treatments

Key takeaways:

• Character Bio is eligible for payments based on future product sales.
• The collaboration may expand into other ocular conditions.

Character Biosciences announced a collaboration with Bausch + Lomb with an initial focus on developing innovative treatments for age-related macular degeneration, according to a press release.

The collaboration will combine Character Bio’s AI-powered analytical engine and patient data platform with Bausch + Lomb’s “extensive expertise in ophthalmology” to drive development, according to the release. In addition to an upfront payment and annual research funding from Bausch + Lomb, Character Bio is eligible for development and sales-related milestone payments as well as tiered royalties contingent on future product sales. Bausch + Lomb will also make a strategic equity investment in Character Bio, subject to closing conditions.

The collaboration has the potential to expand into other eye conditions, according to the release.

“This collaboration represents a pivotal step in applying a data-driven approach to ophthalmology drug development,” Yehia Hashad, MD, chief medical officer and executive vice president of research and development at Bausch + Lomb, said in the release. “We aim to deliver transformative treatments to patients by uncovering novel disease mechanisms and accelerating the development of targeted therapies for AMD.”

Published by:

Read more about

This post was originally published on this site